Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 0.71 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.71 |
| ▸ | CLK2 | P49760 | 1/20 | 0.71 |
| ▸ | CLK3 | P49761 | 1/20 | 0.71 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.71 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.71 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.71 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.71 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.56 |
| ▸ | PIM1 | P11309 | 3/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | PAK4 | O96013 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.53 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27976107 | 0.85 | CLK1 (0.74) | CLK1GSK3BDYRK3CLK2CLK3 | |
| SCHEMBL2455100 | 0.83 | GSK3B (1.00) | CLK1GSK3BDYRK3CLK2CLK3 | |
| SCHEMBL16573980 | 0.81 | GSK3B (0.71) | CLK1GSK3BDYRK3CLK2CLK3 | |
| SCHEMBL27663173 | 0.81 | FGFR1 (0.74) | CLK1GSK3BDYRK3CLK2CLK3 | |
| SCHEMBL16740690 | 0.81 | NOS1 (0.72) | CLK1GSK3BDYRK3CLK2CLK3 | |
| SCHEMBL758312 | 0.81 | FGFR1 (0.77) | CLK1GSK3BDYRK3CLK2CLK3 | |
| SCHEMBL29354575 | 0.81 | FGFR1 (0.77) | CLK1GSK3BDYRK3CLK2CLK3 | |
| SCHEMBL19922226 | 0.81 | CLK1 (0.68) | CLK1GSK3BDYRK3CLK2CLK3 | |
| SCHEMBL729816 | 0.80 | PIK3CA (1.00) | CLK1GSK3BDYRK3CLK2CLK3 | |
| SCHEMBL2457760 | 0.78 | GSK3B (0.66) | CLK1GSK3BDYRK3CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340538-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-11-06 | — | — | US | disclosed |
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-11-06 | — | — | US | disclosed |
| EP-4143185-B1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-10-29 | — | — | EP | disclosed |
| US-12398129-B2 | Imidazolone derivatives as inhibitors of protein kinases in particular DYRK1A, CLK1 and/or CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-08-26 | — | — | US | disclosed |
| CN-118647612-A | Imidazolinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 | 珀哈制药公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4422747-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4422753-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2024-09-04 | — | — | EP | disclosed |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| WO-2023072969-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-05-04 | — | — | WO | disclosed |
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2021-07-08 | — | — | US | disclosed |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2020-04-16 | — | — | US | disclosed |
| US-20190247384-A1 | COMPOSITION FOR ACTIVATING NEUROGENESIS | KYOTO UNIVERSITY (JP) | 2019-08-15 | — | — | US | disclosed |
| EP-3508223-A1 | COMPOSITION FOR ACTIVATING NEUROGENESIS | Kyoto University (JP) | 2019-07-10 | — | — | EP | disclosed |
| EP-1991531-A1 | CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1991540-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007098214-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | CLK1 3184/4885GSK3B 1634/4885DYRK3 4851/4885 |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | RBM17, SFPQ, HNRNPAB | CLK1 3184/4885GSK3B 1634/4885DYRK3 4851/4885 |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | CLK1 1079/4885GSK3B 203/4885DYRK3 1616/4885 |
| US-20250340538-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | CLK1 1/4885GSK3B 582/4885DYRK3 130/4885 |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | CLK1 3184/4885GSK3B 1634/4885DYRK3 4851/4885 |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | CLK1 1270/4885GSK3B 491/4885DYRK3 1993/4885 |
| US-12398129-B2 | Imidazolone derivatives as inhibitors of protein kinases in particular DYRK1A, CLK1 and/or CLK4 | CLK1, CLK2, CLK4 | CLK1 1/4885GSK3B 658/4885DYRK3 108/4885 |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | CLK1 1/4885GSK3B 773/4885DYRK3 104/4885 |
| US-20190247384-A1 | COMPOSITION FOR ACTIVATING NEUROGENESIS | BDNF, GAP43, DCX | CLK1 839/4885GSK3B 17/4885DYRK3 1274/4885 |
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | CLK1, CLK2, CLK3 | CLK1 1/4885GSK3B 739/4885DYRK3 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.